Inhibition of water absorption and selective damage to human colonic mucosa induced by Shiga toxin-2 are enhanced by Escherichia coli O157:H7 infection

International Journal of Medical Microbiology : IJMM
Adriana AlbaneseC Ibarra

Abstract

Shiga toxin-producing Escherichia coli (STEC) strains are responsible for a variety of clinical syndromes including bloody and non-bloody diarrhea, hemorrhagic colitis, and hemolytic uremic syndrome (HUS). Although multiple serotypes of STEC have been isolated from hemorrhagic colitis cases, E. coli O157:H7 is by far the most prevalent serotype associated with HUS. Shiga toxin is the major virulence factor of E. coli O157:H7 and is responsible for the more severe symptoms of the infection. However, the mechanisms involved in the pathogenesis of diarrhea mediated by Stx2 are not well known. In this study, we have determined the effects of E. coli O157:H7 strain 125/99 wild type (wt) on the human colonic mucosa mounted in an Ussing chamber. In response to 125/99wt, an inhibition of water absorption across human colonic mucosa was observed. Histological sections showed severe necrosis with detachment of the surface epithelium, mononuclear inflammatory infiltrate and loss of goblet cells after 1h of incubation with 125/99wt. These alterations were not observed with the isogenic mutant strain lacking stx2 or with the filter-sterilized culture supernatant from the 125/99wt strain. These results indicate that the cell damages in human...Continue Reading

References

Aug 10, 1995·The New England Journal of Medicine·T G BoyceP M Griffin
May 1, 1997·Computer Methods and Programs in Biomedicine·R A DorrM Parisi
Feb 11, 2000·The Journal of Infectious Diseases·X ZhangD W Acheson
Jun 1, 2000·Proceedings of the National Academy of Sciences of the United States of America·K A Datsenko, B L Wanner
Jan 5, 2002·Physiological Reviews·Karl Kunzelmann, Marcus Mall
Mar 26, 2004·Nature Reviews. Microbiology·James B KaperHarry L Mobley
Jul 21, 2004·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·V Pistone CreydtC Ibarra
Oct 21, 2004·International Journal of Medical Microbiology : IJMM·Sylvia HeroldHerbert Schmidt
Aug 8, 2006·Cellular Microbiology·Julian A GuttmanB Brett Finlay
Nov 23, 2006·Computer Methods and Programs in Biomedicine·Mariano E Fernández-MiyakawaCristina Ibarra
Aug 18, 2009·Expert Review of Anti-infective Therapy·Marina S PalermoGabriela C Fernández
Jan 15, 2010·FEMS Immunology and Medical Microbiology·Joanna M LośGrzegorz Wegrzyn
Nov 21, 2012·FEMS Immunology and Medical Microbiology·Tarun BansalArul Jayaraman
Mar 2, 2013·PloS One·Leticia V BentancorMarina S Palermo
Nov 14, 2013·MBio·A LengelingD L Gally

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.